The ATRAID Knockout HAP1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in the HAP1 human chronic myeloid leukemia (CML) cell line, targeting the ATRAID gene. This heterogeneous pool encompasses multiple loss-of-function alleles generated by CRISPR/Cas9-mediated gene disruption, avoiding the selective pressures of clonal isolation while maintaining broad representation of knockout variants. The polyclonal format offers a robust and reproducible model for dissecting ATRAID-dependent phenotypes in a biologically relevant hematopoietic context, without the genetic bottlenecks inherent in single-cell-derived clones. It serves as an essential tool for functional genomics, enabling high-confidence interrogation of gene function in pathways modulated by all-trans retinoic acid (ATRA).
HAP1 cells are derived from the KBM-7 chronic myeloid leukemia line and are distinguished by a near-haploid karyotype, which simplifies genetic analysis and enhances the effectiveness of knockout screening. This cell line retains the BCR-ABL oncogenic fusion, preserving a driver mutation typical of CML and providing a disease-relevant framework for studying malignant hematopoiesis. The haploid nature of HAP1 cells minimizes the confounding effects of diploid compensation, allowing the direct attribution of observed phenotypes to ATRAID disruption. This host background is widely adopted in functional genomics for its tractable genome and compatibility with high-throughput CRISPR-based workflows, making it an ideal platform for investigating genes involved in cell fate decisions and drug sensitivity.
ATRAID is an all-trans retinoic acid-responsive gene that functions as a mediator of ATRA-induced cellular differentiation and programmed cell death. Mechanistically, it operates downstream of retinoic acid receptors (RAR/RXR) and is transcriptionally activated upon ligand binding, integrating signals from ATRA-bound RAR??/RXR heterodimers. Once expressed, ATRAID propagates the differentiation and apoptotic cascade, engaging downstream effectors such as caspase-3 and members of the BCL-2 family to shift the cellular balance toward lineage commitment and apoptosis. The signaling network also involves interaction with cellular retinoic acid-binding proteins (CRABP), which regulate the intracellular availability and transport of ATRA, thereby modulating the amplitude and duration of retinoic acid signaling. Through these molecular connections, ATRAID constitutes a critical node in the retinoic acid-responsive transcriptional program that governs cell cycle exit and differentiation in myeloid cells.
In the context of HAP1 cells, knockout of ATRAID creates a unique model for investigating retinoic acid-dependent processes in a BCR-ABL-positive CML background. The loss of ATRAID function in this near-haploid system eliminates the capacity for retinoic acid-driven differentiation and apoptosis, unmasking resistance mechanisms that may operate in acute myeloid leukemia and other malignancies treated with differentiation therapies. Researchers can exploit this model to screen for synthetic lethal interactions or to identify secondary targets that overcome ATRA resistance. The stable haploid genome ensures that observed phenotypes are attributable to the single disrupted allele, yielding cleaner datasets for transcriptomic and proteomic analyses. This setup is particularly powerful for studying how oncogenic kinase signaling cooperates with or antagonizes retinoic acid receptor-mediated transcription, offering insights into the molecular underpinnings of chemoresistance.
The ATRAID Knockout HAP1 Polyclonal Cells support a broad array of experimental applications, including retinoic acid signaling studies, apoptosis research, and drug sensitivity profiling. Typical workflows involve validation of knockout by Western blotting or RT-qPCR, global transcriptomic analysis via RNA-seq, and functional assessment using cell viability and Annexin V apoptosis assays. Differentiation capacity can be monitored through flow cytometric detection of myeloid markers such as CD11b, while dose-response experiments with ATRA probe the impact of ATRAID loss on chemosensitivity. This model is also suited for CRISPR-based genetic screens aimed at identifying modulators of ATRA response, making it invaluable for cancer biology and differentiation therapy research. For further technical details or to discuss customized applications, please contact Ascent Research.
